Vor Ort
Merkzettel Warenkorb
  • Produktbild: Pathophysiology and Pharmacology of Erythropoietin
  • Produktbild: Pathophysiology and Pharmacology of Erythropoietin

Pathophysiology and Pharmacology of Erythropoietin

99,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

24.11.2011

Abbildungen

XVI, 328 p.

Herausgeber

Horst Pagel + weitere

Verlag

Springer Berlin

Seitenzahl

328

Maße (L/B/H)

23,5/15,5/1,9 cm

Gewicht

528 g

Auflage

Softcover reprint of the original 1st ed. 1992

Sprache

Englisch

ISBN

978-3-642-77076-0

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

24.11.2011

Abbildungen

XVI, 328 p.

Herausgeber

Verlag

Springer Berlin

Seitenzahl

328

Maße (L/B/H)

23,5/15,5/1,9 cm

Gewicht

528 g

Auflage

Softcover reprint of the original 1st ed. 1992

Sprache

Englisch

ISBN

978-3-642-77076-0

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Pathophysiology and Pharmacology of Erythropoietin
  • Produktbild: Pathophysiology and Pharmacology of Erythropoietin
  • List of Contents.- I. Structure and Action.- Structure-Function Relationships of Erythropoietin.- Isoforms of Recombinant Human Erythropoietin.- Activation of the Erythropoietin Receptor in the T3C12 Friend Erythroleukemia Cell Line.- II. Sites and Control of Production.- The Role of Adenosine in Hypoxic Regulation of Kidney Production of Erythropoietin.- Oxygen Shunt Diffusion in Renal Cortex and Its Physiological Link to Erythropoietin Production.- Oxygen Sensing and Erythropoietin mRNA Production in Isolated Perfused Rat Kidneys.- Analysis of Erythropoietin Gene Expression by Means of Competitive Polymerase Chain Reaction.- The Developmental Biology of Erythropoiesis and Erythropoietin: Is Erythropoietin a True Hormone or a Paracrine Factor.- Insulin-like Growth Factor 1 and Erythropoiesis During Growth.- III. Blood Levels in Health and Disease.- Clinical Applicability of the Determination of Erythropoietin.- A Sensitive ELISA for Erythropoietin and Its Application in Various Diseases.- Use of Erythropoietin Radioimmunoassay in Polycythemias.- Effects of Exercise on Plasma Erythropoietin in Natives Living Permanently at High Altitude.- Erythropoietin Concentration in Renal Venous Blood in Patient with Renovascular Hypertension: Is It a Marker of Renal Ischemia.- Serum Erythropoietin Levels in Von Hippel-Lindau Syndrome.- IV. Erythropoietin Replacement in Renal Failure.- Iron Metabolism Under Treatment of Renal Anemia with Recombinant Human Erythropoietin.- Erythropoietin Treatment in Children with Renal Anemia.- Bone Marrow Erythroid Precursor Cytoplasmic Ca2+ and 1, 25-Dihydroxyvitamin D3 Regulate the Response to Human Recombinant Erythropoietin in Uremia: In Vitro and In Vivo Studies.- Dyserythropoietic Abnormalities in Hemodialysis Patients on Long-Term Therapy with Human Recombinant Erythropoietin.- Cardiological Findings in Patients with End-Stage Renal Failure Under Treatment with Erythropoietin.- Long-Term Treatment with Recombinant Human Erythropoietin in Haemodialysis Patients: Effects on Left Ventricular Performance.- Retinal Hypoxia and Anemia in Chronic Renal Failure: Effect of Erythropoietin.- Experience with Subcutaneous Versus Intravenous Administration of Erythropoietin in Haemodialysis Patients.- Pharmacodynamic Aspects of Recombinant Human Erythropoietin - Long-Term Results in Patients with Hemodialysis Treatment.- Comparison of Three Routes of Administration of Recombinant Human Erythropoietin Expressed in C-127 Mouse Cells.- Peritoneal Permeability in Continuous Ambulatory Peritoneal Dialysis After the Correction of Anemia by Erythropoietin.- V. Primary Hemopoietic Disorders and Chemotherapy.- Serum Erythropoietin Levels in Aplastic Anemia Determined by ELISA.- Serum Erythropoietin in Myelodysplasia Syndromes.- Antigenic Characteristics of Erythropoietin-Dependent and -Independent Erythroid Progenitors in Chronic Myeloproliferative Disorders Defined by Monoclonal Antibodies.- Chemotherapy and Erythropoietin Production.- Production of Erythropoietin During and After Thiamphenicol Treatment Occurs Independently of Peripheral Blood Cell Numbers.- VI. Application of Recombinant Erythropoietin in Non-Renal Anemia.- Effects of Inflammatory Cytokines on the Production of Erythropoietin.- The Use of Recombinant Human Erythropoietin in the Treatment of the Anemia of Chronic Disorders.- Recombinant Human Erythropoietin in the Treatment of Anaemia in Rheumatoid Arthritis.- Erythropoietin in Neoplastic Diseases: Preliminary Results.- Erythropoietin Effects on Acute Anemia Induced by Antineoplastic Therapy in the Case of a Uremic Patient with Lymphoma.- The Therapeutic Effect of Recombinant Human Cytokines (GM-CSF, Interleukin-3, Erythropoietin) in Patients with Myelodysplasia Syndromes.- The Effect of Erythropoietin in Chemotherapy-Induced Anaemia in Patients with Osteosarcoma and Ewing’s Sarcoma.- Erythropoietin in Bone Marrow Transplantation: Pathophysiology and Clinical Use.- Experimental and Clinical Results of Perioperative Treatment with Recombinant Human Erythropoietin.